# TROPION-PanTumor01 (NCT03401385)

> First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

No report yet. It can be ordered.

- Drugs tested: datopotamab deruxtecan
- Indication: advanced solid tumors

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03401385
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Daiichi Sankyo Co., Ltd.
- Conditions: Hormone Receptor Positive Breast Cancer; Triple Negative Breast Cancer; Non-small Cell Lung Cancer
- Interventions: Datopotamab Deruxtecan (Dato-DXd); Steroid Containing Mouthwash; Non-Steroid Containing Mouthwash
- Enrollment: 890
- Primary outcome: Number of participants with dose-limiting toxicities
- Primary outcome: Number of participants with adverse events (AEs)
- Primary outcome: Number of participants with Grade >/= 2 oral mucositis/stomatitis in Sub-Study

## Indexed commentary on TROPION-PanTumor01 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 26
- YouTube: 19
- Podcasts: 13

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=tropion-pantumor01-nct03401385

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03401385", "email": "<work email>"}; the inbox owner confirms by the emailed link.